Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 4 May 2021) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

 (PDF, 5MB, 226 pages) 

This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website

 

 

Export 5 results:
Author Title [ Type(Desc)] Year
Filters: Author is Bahmanyar, S.  [Clear All Filters]
Journal Article
A. V. Margulis, Linder, M., Arana, A., Pottegard, A., Berglind, I. A., Bui, C. L., Kristiansen, N. S., Bahmanyar, S., McQuay, L. J., Atsma, W. J., Appenteng, K., D'Silva, M., Perez-Gutthann, S., and Hallas, J., Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom, PLoS One, vol. 13, p. e0204456, 2018.
H. Strongman, Christopher, S., Majak, M., Williams, R., Bahmanyar, S., Linder, M., Heintjes, E. M., Bennett, D., Korhonen, P., and Hoti, F., Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multidatabase cohort study, BMJ Open Diabetes Res Care, vol. 6, p. e000481, 2018.
H. Strongman, Korhonen, P., Williams, R., Bahmanyar, S., Hoti, F., Christopher, S., Majak, M., Kool-Houweling, L., Linder, M., Dolin, P., and Heintjes, E. M., Pioglitazone and risk of mortality in patients with type 2 diabetes: results from a European multidatabase cohort study, BMJ Open Diabetes Res Care, vol. 5, p. e000364, 2017.
P. Korhonen, Heintjes, E. M., Williams, R., Hoti, F., Christopher, S., Majak, M., Kool-Houweling, L., Strongman, H., Linder, M., Dolin, P., and Bahmanyar, S., Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries, Bmj, vol. 354, p. i3903, 2016.
K. Phiri, Hallas, J., Linder, M., Margulis, A., Suehs, B., Arana, A., Bahmanyar, S., Hoffman, V., Enger, C., Horter, L., Odsbu, I., Olesen, M., Perez-Gutthann, S., Kristiansen, N. S., Appenteng, K., de Vogel, S., and Seeger, J., A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder, Curr Med Res Opin, p. 1, 2021.
[Page last reviewed 4 May 2021]